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Abstract
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Patients with schizophrenia often have anxiety and depression, and thus are treated with multiple
psychotherapeutic medications. This practice of polypharmacy increases the possibility for drug–
drug interactions. However, the pharmacological and behavioral mechanisms underlying drug–
drug interactions in schizophrenia remain poorly understood. In the present study, we adopted a
preclinical approach and examined a less known behavioral mechanism, drug–drug conditioning
(DDC) between haloperidol (a typical antipsychotic) or olanzapine (atypical antipsychotic) and
citalopram (a selective serotonin reuptake inhibitor). A rat two-way conditioned avoidance
response paradigm was used to measure antipsychotic activity and determine how DDC may alter
the antipsychotic efficacy in this model. Following acquisition of the avoidance response, rats
were then randomly assigned to receive vehicle, citalopram (10.0 mg/kg, intraperitoneally),
haloperidol (0.05 mg/kg, subcutaneously), olanzapine (1.0 mg/kg, subcutaneously), combined
haloperidol with citalopram, or combined olanzapine with citalopram treatment for seven
avoidance test sessions. In comparison with antipsychotic treatment alone, combined treatment
with citalopram potentiated the antiavoidance effect of olanzapine or haloperidol (to a lesser
extent) during the seven drug-test sessions. In addition, repeated pairing of citalopram with
haloperidol or olanzapine caused citalopram to show a newly acquired avoidance-disruptive
effect. This effect was context specific because citalopram paired with haloperidol or olanzapine
outside the avoidance testing context (i.e. home cages) did not show such an effect. These findings
indicate that concurrent antidepressant and antipsychotic treatments may engender a DDC process
that follows the general Pavlovian associative conditioning principles. They also indicate that
adjunctive citalopram treatment may enhance the antipsychotic efficacy of haloperidol and
olanzapine in the treatment of schizophrenia.
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Introduction
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Depression is a common comorbidity in schizophrenia, affecting an estimated 50% of
patients (Buckley, 2008), and this symptom is often unabated by traditional antipsychotic
regimens. Polypharmacy regimens have often sought to alleviate the depression-related
symptoms by coprescribing an antidepressant along with an antipsychotic drug (Zink et al.,
2010). For example, citalopram (CIT), a selective serotonin reuptake inhibitors (SSRIs) used
for the treatment of major depression (ZumBrunnen and Jann, 1998; Sepehry et al., 2007), is
often used as an adjunctive therapy with traditional antipsychotics in the treatment of
comorbid anxiety and depression symptoms in schizophrenia (Salokangas et al., 1996;
Friedman et al., 2005). This practice of polypharmacy has raised some concerns on the
efficacy, costs, and possible adverse effects of drug–drug interactions (Alfaro, 2001;
Sandson et al., 2005; Conley and Kelly, 2007; Rupnow et al., 2007). Some reports suggest
that antidepressants such as citalopram are effective in the treatment of depression in
schizophrenia with concurrent antipsychotic drug treatment (Englisch et al., 2009; Zisook et
al., 2009). However, other reports question the efficacy of add-on SSRI in the improvement
of negative symptoms (Sepehry et al., 2007). Overall, evidence on augmentation of
antipsychotics with SSRIs remains inconclusive. Also, it is not clear whether the efficacy of
antidepressants or antipsychotics is altered in the combined drug treatment regimens. Zink et
al. (2010) report that there is an urgent need to conduct well-designed randomizedcontrolled trials on the use of antidepressants in schizophrenia. Without controlled trials and
mechanistic investigations, it is difficult to assess the extent and nature of drug–drug
interactions of antidepressants and antipsychotics in the treatment of schizophrenia
(ZumBrunnen and Jann, 1998).

Author Manuscript
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In almost all polypharmacy studies, the focus has been on two major varieties of drug–drug
interactions: pharmacodynamic interactions and pharmacokinetic interactions (Sandson et
al., 2005). Concurrent drug use can also result in a drug–drug conditioning (DDC)
phenomenon that is less understood by psychiatrists. Similar to Pavlovian conditioning
involving exteroceptive stimuli (e.g. light, sound, food, or shock), DDC is found to be
mediated by the same learning principles (Revusky et al., 1979; Taukulis and Brake, 1989).
Taukulis and Brake (1989) reported that the anxiolytic effect of diazepam can be potentiated
by repeatedly pairing it with chlorpromazine. They injected rats with diazepam (2.5 mg/kg),
followed 30 min later by chlorpromazine (10.0 mg/kg). After 10–12 repeated drug pairings
of this type, the anxiolytic responses of the animals to diazepam alone were tested in an
elevated plus maze task. They found that rats previously conditioned with diazepam and
chlorpromazine spent more time in the open arms than rats conditioned with either diazepam
alone or chlorpromazine, followed 30 min later by diazepam (backward pairings). The
results showed that the order of the drugs during the conditioning period was critical to
developing the enhanced anxiolytic effect of diazepam. They later found the same effect
with diazepam–haloperidol (HAL) pairings. Interestingly, other dopamine (DA) antagonists
(thioridazine and pimozide) did not produce an enhanced conditioned response (Taukulis et
al., 1992). This enhanced anxiolytic effect is believed to be caused by the interdrug
conditioning, an internal associative process, rather than pharmacological alteration because
reversing the order of the drug treatment does not change the anxiolysis of diazepam.
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Following a similar approach, we recently examined possible DDC between haloperidol (a
typical antipsychotic) and chlordiazepoxide (a benzodiazepine anxiolytic) and the DDC
between olanzapine (atypical antipsychotic) and chlordiazepoxide in a conditioned
avoidance response (CAR) model (Li et al., 2009). The CAR has been used for the detection
of antipsychotic activity for more than 60 years and shows high predictive validity, as most
antipsychotics at clinically relevant doses disrupt avoidance responding preferentially (Arnt,
1982; Franberg et al., 2008; Porsolt et al., 2010; Wadenberg, 2010). Our results show that
the repeated concurrent chlordiazepoxide and olanzapine treatment attenuated the
antiavoidance effect of olanzapine. However, chlordiazepoxide acquired a haloperidol-like
property in disrupting avoidance responding after being paired repeatedly with haloperidol.

Author Manuscript

The present study used a similar DDC approach and examined how the antidepressant
citalopram interacts with haloperidol or olanzapine (OLZ) in the CAR model. It is known
that both haloperidol and olanzapine disrupt avoidance responding whereas citalopram has
not been shown to disrupt avoidances effectively (Sun et al., 2010). Therefore, it may be
possible that following repeated pairings, citalopram may acquire the avoidance-disruptive
effect of haloperidol or olanzapine. However, repeated combined treatment of citalopram
with haloperidol or olanzapine may alter the effectiveness of haloperidol or olanzapine to
disrupt avoidance. In the present study, citalopram served as a neutral cue [conditioning
stimulus (CS)] that signals that the effects of haloperidol or olanzapine [unconditioned
stimulus (US)] were imminent. Over time, through repeated pairings, citalopram acquired
the avoidance-disruptive property of haloperidol and olanzapine, and also potentiated the
avoidance-disruptive effect of these drugs. These findings indicate that adjunct citalopram
treatment may enhance the antipsychotic efficacy of haloperidol and olanzapine.

Author Manuscript

Methods
Subjects
Male Sprague–Dawley rats (226–250 g upon arrival; Charles River Laboratories, Potage,
Michigan, USA) were housed two per cage in 48.3 cm × 26.7 cm × 20.3 cm transparent
polycarbonate cages under 12-h light/dark conditions (light on between 06:30 and 18:30 h).
Room temperature was maintained at 21±1° with a relative humidity of 45–60%. Food and
water were freely available. Animals were allowed at least 1 week of habituation to the
animal facility before being used in the experiments. All procedures were approved by the
Institutional Animal Care and Use Committee at the University of Nebraska, Lincoln.
Avoidance conditioning apparatus

Author Manuscript

Eight identical two-way shuttle boxes, custom designed and manufactured by Med
Associates (St Albans, Vermont, USA), were used. Each box was housed in a ventilated,
sound-insulated isolation cubicle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was
64 cm long, 30 cm high (from grid floor), and 24 cm wide, and divided into two equal-sized
compartments by a white PVC partition with an arch-style doorway (15 cm H × 9 cm W at
base). An aluminum hurdle (4 cm high) was placed between the two compartments; thus, the
rats had to jump from one compartment to enter the other. The grid floor consisted of 40
stainless-steel rods, spaced 1.6 cm apart center to center, through which a scrambled
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footshock (0.8 mA) was delivered by a constant current shock generator (Model ENV-410B)
and scrambler (Model ENV-412). The rat’s location and motor activity were detected by a
set of 16 photobeams (ENV-256-8P) affixed at the bottom of the box (3.5 cm above the grid
floor). A speaker (ENV-224AMX) mounted on the ceiling of the cubicle, centered above the
shuttle box, was used to provide a CS (76 dB white noise). All the training and testing
procedures were controlled by Med Associates programs running on a computer.
Background noise (~ 74 dB) was provided by a ventilation fan affixed at the top corner of
each isolation cubicle.
Experiment 1: Effects of repeated citalopram and haloperidol pairing on avoidance
responding to citalopram and haloperidol
The experiment comprised of three phases: avoidance training, DDC, and drug testing (see
Fig. 1 for the procedural details).

Author Manuscript
Author Manuscript

Avoidance training phase—Forty rats were first handled and habituated to the
avoidance conditioning apparatus for two days (30 min/day), and then trained for 10
consecutive days to acquire robust conditioned avoidance responding (> 70% avoidance
trials). Each training session consisted of 30 discrete trials. Every trial started by presenting
white noise (CS, 76 dB) for 10 s, followed by a continuous footshock (US, 0.8 mA,
maximum 5 s) on the grid floor. If a subject moved from one compartment into the other
within the 10 s of CS presentation, the shock was prevented, and this shuttling response was
recorded as avoidance (a two-way avoidance). If the rat remained in the same compartment
for more than 10 s and made a crossing upon receiving the footshock, this response was
recorded as escape. If the rat did not respond during the entire 5-s presentation of the shock,
the trial was terminated and escape failure was recorded. Intertrial intervals varied randomly
between 30 and 60 s.

Author Manuscript

Drug conditioning phase—At the end of the training phase, 32 rats that had fulfilled the
training criterion (≥ 70% avoidance in each of the last two sessions) were used in the drug
conditioning phase. They were matched and then assigned randomly to one of the four
groups. The drug conditioning phase consisted of a 3-day cycle and was repeated seven
times over a 21-day period. On day 1, each group was administered a double injection of
one of the following combinations: CIT + VEH (n = 8), VEH + HAL (n = 8), CIT + HAL (n
= 8), and VEH + VEH (n = 8). The first injection (CIT 10.0 mg/kg, or sterile water, 1.0
ml/kg, intraperitoneally) was administered 15 min before the second injection (HAL 0.05
mg/kg, or sterile water, 1.0 ml/kg, subcutaneously). One hour after the second injection, rats
were placed in the avoidance conditioning boxes and tested. On day 2, rats in the CIT +
VEH, VEH + HAL, and CIT + HAL groups received a single injection of HAL, CIT, and
VEH, respectively, whereas the VEH + VEH group received a double injection of CIT and
HAL separated by 15 min. Immediately after the injections, rats were returned to their home
cages. No avoidance test was carried out on this day. The purpose of giving rats the drug
treatments on day 2 and not testing them was to ensure that every rat received the same drug
treatment (all rats had CIT, HAL, and VEH), although in different contexts (e.g. home cage
vs. CAR boxes) and with different drug injection intervals (15 min vs. 24 h), so that the
specific DDC effect on avoidance behavior could be assessed. On day 3, all rats were
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untreated and unhandled. Following the seven cycles of the conditioning procedure, all rats
were retrained drug-free in two consecutive sessions to bring back a high level of avoidance
responding.
Drug testing phase—The drug testing phase started 24 h after the last retraining session.
Rats were first injected with CIT (10.0 mg/kg, intraperitoneally) and tested 75 min later. The
next day, rats were retrained drug-free, and 1 day later, tested again under HAL (0.025
mg/kg, subcutaneously, − 60 min) to assess the HAL sensitization effect (Li et al., 2010;
Mead and Li, 2010; Zhang and Li, 2012). For both drug tests, the same conditioned
avoidance procedure was used, except that only the CS was presented in the 30 trials. No
shock US was ever presented.

Author Manuscript

Experiment 2: Effects of repeated citalopram and olanzapine pairing on avoidance
responding to citalopram and olanzapine
This experiment was identical to experiment 1, except that HAL was replaced by OLZ.
Forty rats were used, of which 32 rats that fulfilled the learning criterion were used in the
drug testing. They were assigned to one of the following four groups: CIT + VEH (n = 8),
VEH + OLZ (n = 8), CIT + OLZ (n = 8), and VEH + VEH (n = 8), and were subjected to the
seven sessions of drug conditioning and two sessions of drug testing (the CIT test, followed
by the OLZ 0.5 mg/kg test) to assess the CIT conditioning effect and the OLZ sensitization
effect.
Drugs

Author Manuscript
Author Manuscript

The injection solutions of HAL (5 mg/ml ampoules, Shanghai Xudong Haipu
Pharmaceutical Co., Shanghai, China) and CIT (Toronto Research Chemicals Inc., Toronto,
Ontario, Canada) were obtained by mixing drugs with sterile water. OLZ (a gift from the
National Institute of Mental Health drug supply program) was dissolved in 1.5% glacial
acetic acid in distilled water. HAL and OLZ were administered subcutaneously, whereas
CIT was administered intraperitoneally. The doses of HAL (0.05 mg/kg) and OLZ (1.0
mg/kg) and their injection route were chosen on the basis of (a) previous work showing that
at the chosen doses, HAL and OLZ injected subcutaneously produce a comparable
progressive across-session decrease in avoidance responding (Li et al., 2007) and (b) rat
brain D2 receptor occupancy data showing that both drugs induce clinically comparable
levels of D2 occupancy (65–80%) (Kapur et al., 2003). The choice of the CIT dose (10
mg/kg) and its route of injection was made on the basis of the findings showing that (a) CIT
(10 mg/kg) is ineffective in disrupting avoidance responding (Sun et al., 2010) and (b) CIT
at this dose is effective in several aversively conditioned paradigms, such as Pavlovian fear
conditioning (Hashimoto et al., 2009; Sun et al., 2010).
This time interval between CIT and HAL or OLZ (15 min) was determined so that there was
sufficient time for the drug effects of HAL or OLZ and CIT to overlap. The half-lives of
CIT, HAL, and OLZ in rats are 3 h (Hyttel et al., 1984), 1.5 h (Cheng and Paalzow, 1992),
and 2.5 h (Aravagiri et al., 1999), respectively. This arrangement ensures that the two drugs
had sufficient concurrency of the effective drug states that would be suitable for DDC. A
similar kind of DDC arrangement had been used by Taukulis and Brake (1989). To
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determine possible behavioral sensitization induced by repeated HAL or OLZ treatment,
HAL and OLZ were administered at half of their training doses during the last test session
(0.025 and 0.5 mg/kg, respectively) (Li et al., 2010; Zhang and Li, 2012).
Statistics

Author Manuscript

The main dependent variable was the number of avoidance responses. All data are expressed
as mean ± SEM. Data from the DDC phase were first analyzed using a mixed-model
repeated-measures analysis of variance (ANOVA) with CIT (CIT vs. VEH, two levels),
HAL (HAL vs. VEH, two levels), or OLZ (OLZ vs. VEH, two levels) as the betweensubjects factor and the test sessions (i.e. seven drug sessions) as the within-subjects factor,
followed by post-hoc Fisher’s protected least squared difference to identify the significant
group differences. A similar repeated-measures analysis was used for the two consecutive
drug-free retraining days. For the drug challenge test days (CIT, HAL, or OLZ challenge
tests), because we had an a-priori hypothesis on the basis of our previous work (Li et al.,
2009), a series of planned comparisons instead of post-hoc tests were used to identify
significant differences between groups. A conventional two-tailed level of significance at
the 5% level was used.

Results
Experiment 1: Effects of repeated citalopram and haloperidol pairing on avoidance
responding to citalopram and haloperidol

Author Manuscript

CIT and HAL: conditioning—HAL potently and progressively attenuated avoidance
responding (Fig. 2a). There was a significant main effect of HAL [F(1,28) = 316.56, P <
0.001] as well as a significant HAL × Session interaction [F(6,168) = 14.47, P < 0.001]. The
main effect of CIT was marginally significant [F(1,28) = 4.17, P = 0.05], whereas the CIT ×
Session interaction was not significant. Examination of the pattern of avoidance responding
across sessions showed that rats treated with VEH + VEH maintained a high level of
responding, whereas rats treated with CIT + VEH had somewhat attenuated responding. The
VEH + HAL rats showed a rapid and progressive attenuation across test sessions and those
treated with CIT + HAL tended to have the lowest levels of avoidance responding.
CIT did not alter the number of escape failures. However, there was a significant main effect
of HAL [F(1,28) = 26.01, P < 0.001] and a significant HAL × Session interaction [F(6,168)
= 14.06, P < 0.001], wherein animals treated with HAL showed a progressive increase in
their number of escape failures across test sessions (Fig. 2b).

Author Manuscript

CIT and HAL: drug-free retraining—During the subsequent two drug-free retraining
sessions, rats that had received HAL treatment (i.e. VEH + HAL or CIT + HAL) recovered
avoidance responding (Fig. 2a). There was a significant CIT × HAL × Session interaction
[F(1,28) = 70.05, P < 0.02], a significant CIT × Session interaction [F(1,28) = 7.05, P <
0.02], and a significant HAL × Session interaction [F(1,28) = 31.54, P < 0.001], wherein
rats treated with VEH + HAL performed the least number of avoidance responses on the
first retraining day, whereas those that received CIT + HAL performed at intermediate levels
and those that received VEH + VEH or CIT + VEH performed the highest number of
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avoidance responses. On the first day of retraining, there were significant main effects of
HAL [F(1,28) = 34.50, P < 0.001] and CIT (F(1,28) = 6.30, P < 0.02) and a significant CIT
× HAL interaction [F(1,28) = 6.88, P < 0.02]. One-way ANOVA, followed by post-hoc
analysis showed that rats that had been treated previously with CIT + HAL made
significantly fewer avoidance responses than those treated previously with VEH + VEH or
CIT + VEH (P < 0.05). Furthermore, rats treated previously with VEH + HAL performed
fewer avoidance responses than the VEH + VEH, CIT + VEH, or CIT + HAL rats. On the
second retraining day, there was a significant main effect of HAL [F(1,28) = 9.75, P <
0.005], wherein rats treated with HAL made significantly fewer avoidance responses than
those not treated previously with HAL.

Author Manuscript

On escape failures, across the two-day retraining period (Fig. 2b), there were significant
effects of CIT [F(1,28) = 5.10, P < 0.05], HAL [F(1,28) = 9.52, P < 0.005], and the CIT ×
HAL interaction [F(1,28) = 10.05, P < 0.005]. In addition, there was a significant HAL ×
Session interaction [F(1,28) = 9.75, P < 0.005]. Post-hoc analysis showed that during the
first retraining session, rats that had been treated in the shuttle box with VEH + HAL had a
greater number of escape failures than those treated with CIT + HAL, CIT + VEH, or VEH
+ VEH.

Author Manuscript

CIT and HAL: CIT challenge test—During the CIT test, all rats were treated with CIT
(10.0 mg/kg, intraperitoneally) to determine the DDC effects of CIT to HAL (Fig. 3).
Planned comparisons of the four conditioning groups showed that rats treated with VEH +
VEH or CIT + VEH did not differ from each other and maintained a high level of avoidance
responding. Rats that had been treated previously with VEH + HAL also did not differ
significantly from these two groups. However, rats had been conditioned to CIT + HAL
showed the fewest avoidance responses and were significantly different from the VEH +
VEH or the CIT + VEH rats (P values < 0.05). This indicates that CIT + HAL conditioning
resulted in CIT acquiring the avoidance-disrupting effects of HAL. In addition, this effect
was specific to the conditioned effects of the drugs in the testing context because rats that
received CIT + HAL pairings in their home cage did not show this effect.

Author Manuscript

CIT and HAL: HAL challenge test—Following a subsequent retraining day (no group
differences present; Fig. 4, inset), all rats were administered a 0.025 mg/kg HAL injection
and their avoidances were tested 1 h later to assess HAL sensitization (Fig. 4) (Li et al.,
2010). Planned comparisons showed no difference between rats treated previously with CIT
+ VEH or VEH + VEH. However, rats treated previously with VEH + HAL or CIT + HAL
performed significantly fewer avoidance responses than the CIT + VEH or VEH + VEH
groups (P values < 0.05). There were also no differences between the two HAL groups.
These data indicate that repeated administration of HAL induced a long-lasting sensitization
effect in avoidance disruption, consistent with our previous finding (Li et al., 2007; Zhang
and Li, 2012). In addition, CIT did not alter the efficacy of HAL even after repeated
pairings.
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Experiment 2: Effects of repeated citalopram and olanzapine pairing on avoidance
responding to citalopram and olanzapine
CIT and OLZ: conditioning—Repeated administration of OLZ potently and
progressively attenuated avoidance responding across the seven drug test sessions (Fig. 5a).
In contrast, rats treated with VEH + VEH or CIT + VEH maintained a high level of
responding, and they did not differ from one another. There was a significant main effect of
OLZ [F(1,28) = 316.56, P < 0.001] and a significant OLZ × Session interaction [F(6,168) =
13.76, P < 0.001]. In addition, there was a significant main effect of CIT [F(1,28) = 316.56,
P < 0.001] and a significant CIT × Session interaction [F(6,168) = 30.05, P < 0.01], wherein
CIT reduced the number of avoidance responses. This was especially evident during the first
four drug-test sessions.
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Analysis of escape failures showed that repeated administration of OLZ progressively
increased the number of escape failures across sessions (Fig. 5b). Rats treated with VEH +
VEH or CIT + VEH maintained very low levels of escape failures and they did not differ
from one another. There was a significant main effect of OLZ [F(1,28) = 34.37, P < 0.001]
and a significant OLZ × Session interaction [F(6,168) = 13.87, P < 0.001].

Author Manuscript

CIT and OLZ: drug-free retraining—During the subsequent two drug-free retraining
sessions, rats that had received OLZ treatment recovered at a slower rate compared with
VEH-treated rats or rats that received CIT alone. A repeated-measures ANOVA showed a
significant main effect of OLZ [F(1,28) = 16.66, P < 0.001; Fig. 5a]. Rats that had been
treated previously with VEH + OLZ or CIT + OLZ made significantly fewer avoidance
responses on both days. The VEH + OLZ and CIT + OLZ groups were significantly
different from the VEH + VEH or CIT + VEH groups (P’s < 0.05) on the first retraining
day. The CIT + OLZ group was still significantly different from the VEH + VEH or the CIT
+ VEH group on the second retraining day (P < 0.05).
In terms of escape failures, there was a significant main effect of OLZ [F(1,28) = 4.412, P <
0.05; Fig. 5b]; however, the difference between group means was less than one trial and was
probably not psychologically significant.

Author Manuscript

CIT and OLZ: CIT challenge test—Following two retraining days, all rats were treated
with CIT to determine the DDC effect of CIT to OLZ (Fig. 6). Rats treated with VEH +
VEH or CIT + VEH during the DDC sessions maintained a high level of avoidance
responding and they did not differ from one another. Also, rats treated with VEH + OLZ
were not different from any group. However, planned comparisons showed that rats that had
been treated previously with CIT + OLZ made significantly fewer avoidance responses than
CIT + VEH (P < 0.005) or VEH + VEH (P < 0.005). This indicates that CIT + OLZ
conditioning resulted in CIT acquiring the avoidance-disrupting effects of OLZ. In addition,
this effect was specific to the conditioned effects of the drugs in the testing context because
animals that experienced CIT + OLZ pairings in their home cage did not show this effect.
CIT and OLZ: OLZ challenge—On the subsequent retraining day, although they
achieved an average of 25.5 avoidances, rats conditioned with CIT + OLZ still made
significantly fewer avoidance responses than those conditioned with CIT + VEH or VEH +
Behav Pharmacol. Author manuscript; available in PMC 2016 February 16.
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VEH (P < 0.05; Fig. 7, inset). To examine the long-term sensitization effect of OLZ (Li et
al., 2010; Mead and Li, 2010; Zhang and Li, 2012), all rats were administered a 0.5 mg/kg
OLZ injection and their avoidances were tested (Fig. 7). One-way ANOVA showed a
significant effect of group [F(3,28) = 13.73, P < 0.001] and subsequent planned
comparisons showed that rats treated previously with VEH + OLZ or CIT + OLZ during the
DDC phase made significantly fewer avoidance responses than those treated previously with
VEH + VEH (P values < 0.05). Interestingly, rats previously conditioned to CIT + VEH also
made fewer avoidance responses than the VEH + VEH-treated rats (P < 0.001), but more
than the rats conditioned to CIT + OLZ (P < 0.04) or VEH + OLZ (P < 0.02). These results
indicate that CIT + VEH treatment also enhanced rats’ sensitivity to the avoidancedisruptive effect of OLZ. However, this effect was weak in comparison with the effects of
OLZ treatment and was dependent on the context of the drug experience, as the VEH + VEH
rats receiving CIT + OLZ pairings in their home cage did not show this enhanced sensitivity.

Author Manuscript

Discussion

Author Manuscript

In two separate studies, we examined how the SSRI CIT interacted behaviorally with the
typical antipsychotic HAL or the atypical antipsychotic OLZ as a means to examine the
impact of polypharmacy treatment in schizophrenia. Our results clearly show that when two
psychotropic drugs are used together, their behavioral effects could be altered by a DDC
mechanism. For example, CIT by itself does not have an intrinsic disruptive effect on the
CAR (Figs 2a and 5a) (Sun et al., 2010): however, after repeated pairings with HAL or
OLZ, it acquired an antiavoidance property (Figs 3 and 6). This ‘acquired’ avoidancedisruptive effect of CIT was attributed specifically to DDC, wherein CIT functioned as the
drug CS and HAL or OLZ as the drug US (Taukulis and Brake, 1989), and could not be
attributed to the simple pharmacological effects of the drugs, as no such effect was found in
the control groups (e.g. the CIT + VEH, VEH + HAL, or VEH + OLZ), even though they
received the same numbers of CIT and HAL or OLZ injections separated by 24 h. We also
found that, to induce the antiavoidance effect in the CIT group, CIT + HAL or CIT + OLZ
pairing had to occur within the context of avoidance testing. Rats that received this pairing
in their home cages (i.e. VEH + VEH rats) did not show altered drug efficacy in the CAR
procedure. These findings indicate that the drug conditioning is context specific. They also
indicate that the drug conditioning effects follow the same general associative conditioning
principles found in a typical Pavlovian conditioning paradigm in which a deliberate CS–US
pairing is required (Domjan, 2005).
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In addition, the combined treatment of CIT with HAL or OLZ potentiated the avoidancedisruptive effect of HAL and OLZ during the DDC phase. This effect may be mediated by
the pharmacological mechanisms associated with the pharmacokinetic or pharmacodynamic
interactions of the drugs. Pharmacokinetically, most antipsychotics and SSRIs are
metabolized through the CYP isozyme system (mainly CYP1A2, CYP2D6, and CYP3A4)
and, as a result, SSRIs can inhibit the metabolism of antipsychotic drugs (ZumBrunnen and
Jann, 1998). In the case of CIT (CYP2C19, CYP2D6, and CYP3A4) (Spina et al., 2008),
extant evidence suggests that the impact of pharmacokinetic interaction is minimal.
Combined treatment with CIT and HAL (Syvalahti et al., 1997) or CIT and OLZ (Botts et
al., 2008) did not cause significant changes in the plasma concentrations of HAL or OLZ in
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humans and possibly in rats. This leaves the pharmacodynamic interaction as the most likely
factor contributing toward the enhanced antiavoidance effect. Indeed, several studies have
reported that the central (brain) effects of HAL and OLZ are enhanced by CIT or other
SSRIs. For example, Waldmeier and Delini-Stula (1979) reported that CIT potentiated the
increase in striatal deaminated DA metabolites (homovanillic acid and 3,4dihydroxyphenylacetic acid) induced by HAL. Behaviorally, CIT also potentiated HALinduced catalepsy and its antagonism of apomorphine-induced stereotypies. Huang et al.
(2006) found that CIT increased extracellular DA and norepinephrine efflux in rat medial
prefrontal cortex induced by risperidone. Others have also shown that fluoxetine increases
the release of DA and norepinephrine in the medial prefrontal cortex induced by OLZ (Koch
et al., 2004). These augmented neurochemical effects by CIT on HAL or OLZ may explain
the potentiated antiavoidance effect in the present study and the potentiated therapeutic
effects on affective symptoms in the clinic (Zink et al., 2010). Because the antipsychotic
action, as well as the antiavoidance effect of HAL and OLZ, is shown to be mediated by the
antagonism of D2 receptors (Wadenberg et al., 2001; Li et al., 2010), CIT may increase the
antagonistic action of HAL and OLZ on D2 receptors through its selective inhibition of
reuptake of 5-HTand increase of 5-HTrelease in the medial prefrontal cortex (Huang et al.,
2006). Another possibility is that the increased level of 5-HT by CIT treatment may
stimulate 5-HT2C receptors to exert a disruptive effect on avoidance responding. This
hypothesis is supported by the evidence showing that 5-HT2C receptor agonists such as 2,5dimethoxy-4-iodo-amphetamine (DOI), 1-(3-chlorophenyl) piperazine (mCPP), and the 5HT2A/2C receptor agonist D-LSD disrupt the avoidance response (Wadenberg and Hicks,
1999; Li et al., 2010). It is also consistent with the findings that the activation of 5-HT2C
receptors decreases DA release in the nucleus accumbens and cell firing in the ventral
tegmental area (Di Giovanni et al., 2000; Di Matteo et al., 2002), the mesolimbic DA
system that is implicated in the CAR (Wadenberg and Hicks, 1999).
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In recent years, we have shown that the repeated administration of HAL and OLZ induces a
behavioral sensitization in the CAR model (Li et al., 2010; Mead and Li, 2010; Zhang and
Li, 2012). This sensitization effect can be found in a challenge test (i.e. re-exposure to the
drug) in which antipsychotic-treated animals show a stronger response (i.e. lower avoidance)
to the drug than drug-naive animals (Mead and Li, 2009; Zhang et al., 2011; Zhang and Li,
2012). It is also long-lasting, producing an effect that can be observed up to 3 weeks later
(Mead and Li, 2009) and is subject to contextual and behavioral controls (Zhang and Li,
2012). The results from the present study are consistent with these previous observations
(Figs 4 and 7). In the current study, rats treated with HAL or OLZ (i.e. VEH + HAL or CIT
+ HAL; VEH + OLZ or CIT + OLZ) in the CAR testing apparatus showed enhanced
responses to a challenge dose of HAL or OLZ compared with those treated with the same
drugs outside of the CAR apparatus. More interestingly, CIT treatment did not alter this
long-term treatment effect of HAL or OLZ, as there was no significant difference between
the two HAL (VEH + HAL or CIT + HAL) or two OLZ (VEH + OLZ or CIT + OLZ)
groups on the challenge tests. Our recent work indicates that the activation of 5-HT2A/2C
receptors by DOI (a 5-HT2A/2C receptor agonist) can attenuate HAL-induced and (to a lesser
extent) OLZ-induced sensitization of avoidance responding (Li et al., 2010). The failure of
CIT, but not DOI, to modulate HAL and OLZ sensitization might reflect differences
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between changes in the synaptic levels of 5-HT produced by reuptake inhibition and the
direct stimulation of 5-HT2A/2C receptors.
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As mentioned in the Introduction section, most schizophrenic patients are treated with
multiple psychotherapeutic drugs (ZumBrunnen and Jann, 1998; Zink et al., 2010).
Combined SSRIs and antipsychotic therapies are also used widely in the treatment of major
depressive disorders and especially in hard-to-treat and treatment-refractory patients
(DeBattista and Hawkins, 2009). There are also drugs (e.g. Symbyax) with this drug
combination built in (DeBattista and DeBattista, 2010). The current studies are important in
understanding the psychological interactions associated with the polypharmacy treatment of
schizophrenia-related spectrum disorders and comorbidities. The methodology of these
studies effectively models the acute antipsychotic actions of drugs and their progressive
effectiveness over time. The dynamics of drug efficacy may be of considerable importance
in predicting both acute and long-term behavioral outcomes. As the current studies indicate,
these drugs can have behavioral interactions that are well beyond the traditionally
considered pharmacological interactions. These studies show that SSRIs, such as CIT, may
augment the behavioral effects of both typical and atypical antipsychotics, although to date,
this interaction has not been observed in a clinical setting. It is important to consider that at
clinically relevant doses, drugs may interact at a behavioral level in ways that may either be
efficacious or harmful in real-world use. Furthermore, these studies reinforce the idea that
the experiential context of drug action may be an important part of drug efficacy and may
play a role in drug maintenance and symptom relapse.
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Besides its contribution in providing a preclinical approach to the study of polypharmacy in
the treatment of schizophrenia, the present study is also important because it extends
psychopharmacology research on antipsychotic drugs utilizing a Pavlovian DDC paradigm
(Li et al., 2009). First, it shows that an instrumental conditioned active motor behavior can
also be used as a valid index to evaluate the drug conditioning effect. This is different from
many previous drug conditioning studies that typically use simple physiological measures or
reactive responses, such as drug-induced thermic effects, heart rate, stomach emptying,
muscle relaxation, or taste aversions (Wilkin et al., 1982; Revusky et al., 1989; Davey and
Biederman, 1991; Reilly and Revusky, 1992; Biederman and Davey, 1993). Second, as
discussed in our previous publication (Li et al., 2009), it introduces a new approach to
examine the effects of DDC. In many drug conditioning studies, the drug conditioning effect
is often indexed by some change in one or more of the intrinsic properties of the CS drug
(Taukulis, 1996). For example, in a series of studies on the diazepam–haloperidol or
diazepam–chlorpromazine conditioning (Taukulis and Brake, 1989; Taukulis et al., 1992),
the drug conditioning was evidenced by the altered drug properties of diazepam, such as
enhanced hypothermia, reduced muscle relaxation, and enhanced anxiolytic effect. In the
present study, the conditioning effect was observed in the newly ‘acquired’ avoidancedisruptive effect of CIT, which is not an intrinsic drug property of CIT. This approach
provides an unequivocal demonstration of the DDC effect. Finally, it indicates that SSRIs
can also be used as a CS drug to study the behavioral and neurobiological mechanisms
underlying drug–drug interactions. Together with our previous work with chlordiazepoxide
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(Li et al., 2009), it appears that DDC may be a general process applicable to multiple
psychotropic drugs.

Conclusion
Our results show that the concurrent use of CIT with HAL or OLZ caused a potentiation of
the avoidance-disruptive effect of both antipsychotic drugs. Conversely, the behavioral
effect of CIT was altered by HAL or OLZ through a DDC process, so that CIT acquired an
additional avoidance-disruptive effect (an antipsychotic-like effect) after being combined
repeatedly with HAL or OLZ. Our work provides a preclinical approach to examine the
extent and mechanisms of drug–drug interactions among antipsychotics and antidepressants
in the treatment of schizophrenia.
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Fig. 1.

A schematic depiction of the experimental procedure in experiment 1. CAR, conditioned
avoidance response; CIT, citalopram; HAL, haloperidol; VEH, vehicle.
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Fig. 2.

Experiment 1: Number of avoidances (a) and escape failures (b) made by the rats in the four
groups during the last predrug session, seven drug conditioning sessions, and two drug-free
retraining sessions. Points represent mean±SEM. *Differs significantly (P < 0.05) from CIT
+ VEH and VEH + VEH; #differs significantly (P < 0.05) from CIT + HAL. CIT,
citalopram; HAL, haloperidol; VEH, vehicle.
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Fig. 3.

Experiment 1: Number of avoidances during the CIT challenge test. All rats were injected
with CIT (10 mg/kg, intraperitoneally) and tested 75 min later. Points represent mean±SEM.
*Differs significantly (P < 0.05) from CIT + VEH and VEH + VEH. CIT, citalopram; HAL,
haloperidol; VEH, vehicle.
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Fig. 4.

Experiment 1: Number of avoidances during the HAL challenge test. All rats were injected
with HAL (0.025 mg/kg) and tested 60 min later. Points represent mean±SEM. *Differs
significantly (P < 0.05) from CIT + VEH and VEH + VEH. Inset shows the number of
avoidances from the drug-free retraining session conducted 1 day before. CIT, citalopram;
HAL, haloperidol; VEH, vehicle.
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Fig. 5.

Experiment 2: Number of avoidances (a) and escape failures (b) made by the rats in the four
groups during the last predrug session, seven drug conditioning sessions, and two drug-free
retraining sessions. Points represent mean±SEM. *VEH + OLZ and CIT + OLZ differ
significantly (P < 0.05) from the VEH + VEH or CIT + VEH; #CIT + OLZ differ
significantly from the VEH + VEH and CIT + VEH. CIT, citalopram; HAL, haloperidol;
OLZ, olanzapine; VEH, vehicle.
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Fig. 6.

Experiment 2: During the CIT challenge test. All rats were injected with CIT (10 mg/kg,
intraperitoneally) and tested 75 min later. Points represent mean±SEM. *Differs
significantly (P < 0.05) from CIT + VEH and VEH + VEH. CIT, citalopram; OLZ,
olanzapine; VEH, vehicle.
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Fig. 7.

Experiment 2: Number of avoidances during the OLZ challenge test. All rats were injected
with OLZ (0.5 mg/kg) and tested 60 min later. Points represent mean±SEM. *Differs
significantly (P < 0.05) from CIT + VEH and VEH + VEH. #Differs significantly (P < 0.05)
from VEH + OLZ, CIT + OLZ and VEH + VEH. Inset shows the number of avoidances
from the drug-free retraining session conducted 1 day before. CIT, citalopram; OLZ,
olanzapine; VEH, vehicle.
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